In recent years, the focus of clinical development has been on immunotherapeutic compounds aimed at clearing brain ...

Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the mid-stage study has been tied to one death. | Early data suggest ...

Alzheimer's disease is the most common cause of dementia in the elderly and is characterized by abnormal deposits of amyloid-beta and tau proteins in the brain. This disease has a ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

The clumping of amyloid beta in the brain to form plaques is one the hallmarks of AD, and the 'amyloid hypothesis' suggests they are a primary driver for the neurodegeneration seen in the disease.

The technology – called Antibody Transport Vehicle (ATV): Amyloid beta – can be used to help amyloid-targeting drugs cross the blood brain barrier (BBB) more effectively, say the partners.

Alzheimer's disease, the leading cause of dementia, affects over 55 million people worldwide. The disease is characterized by ...

Maturing Plaques. The oldest plaques (left) contain β-sheets (red) and dense fibrillar cores (blue), while younger plaques (middle) lack dense cores, and the youngest (right) lack either. [Courtesy of ...

Drs Pavan Brahmbhatt and Amit Agarwal discuss best practices for managing amyloid-related imaging abnormalities in patients ...

Amyloid fibrils appear in many neurodegenerative diseases, and scientists are eager to understand how they form and spread.

An international team led by researchers at the University of Toronto has developed an efficient and robust system, using the C. elegans nematode, to screen for compounds that can stop the growth of ...

single-injection once-monthly antibody delivered subcutaneously for the treatment of Alzheimer's disease that targets a key epitope at the N-terminus of amyloid beta (Aß) with high binding potency.